Anidulafungin
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Candidemia
Conditions
Candidemia
Trial Timeline
Jan 1, 2008 → Mar 1, 2009
NCT ID
NCT00537329About Anidulafungin
Anidulafungin is a phase 3 stage product being developed by Pfizer for Candidemia. The current trial status is completed. This product is registered under clinical trial identifier NCT00537329. Target conditions include Candidemia.
What happened to similar drugs?
4 of 7 similar drugs in Candidemia were approved
Approved (4) Terminated (2) Active (2)
🔄Fosmanogepix + Fosmanogepix + Caspofungin + Fluconazole + Placebo + Placebo + Placebo + PlaceboBasilea PharmaceuticaPhase 3
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01202253 | Pre-clinical | Completed |
| NCT00934934 | Phase 2 | Terminated |
| NCT01053884 | Phase 2 | Terminated |
| NCT00537329 | Phase 3 | Completed |
| NCT00056381 | Phase 1/2 | Completed |
Competing Products
9 competing products in Candidemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| micafungin + Micafungin + Caspofungin | Astellas Pharma | Approved | 43 |
| Micafungin | Astellas Pharma | Approved | 35 |
| AmBisome | Gilead Sciences | Approved | 43 |
| Anidulafungin/Fluconazole | Pfizer | Phase 3 | 32 |
| Anidulafungin + Voriconazole | Pfizer | Approved | 43 |
| Anidulafungin + Fluconazole | Pfizer | Phase 3 | 40 |
| Fosmanogepix + Fosmanogepix + Caspofungin + Fluconazole + Placebo + Placebo + Placebo + Placebo | Basilea Pharmaceutica | Phase 3 | 41 |
| APX001 | Basilea Pharmaceutica | Phase 2 | 29 |
| APX001 | Basilea Pharmaceutica | Phase 2 | 29 |